Brentuximab for Newly Diagnosed Hodgkin Disease
Palo Alto (17 mi)Overseen byJessica Hochberg, MD
Age: < 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Mitchell Cairo
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Approved in 2 jurisdictions
Trial Summary
What is the purpose of this trial?The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).
Eligibility Criteria
Treatment Details
3Treatment groups
Experimental Treatment
Group I: Low RiskExperimental Treatment3 Interventions
Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
Group II: Intermediate RiskExperimental Treatment4 Interventions
Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
Group III: High RiskExperimental Treatment4 Interventions
High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy
Brentuximab Vedotin is already approved in United States, European Union for the following indications:
🇺🇸 Approved in United States as Adcetris for:
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
- Primary cutaneous anaplastic large cell lymphoma
- CD30-expressing mycosis fungoides
- Peripheral T-cell lymphoma
🇪🇺 Approved in European Union as Adcetris for:
- Hodgkin lymphoma
- Systemic anaplastic large cell lymphoma
- Cutaneous T-cell lymphoma
Find a clinic near you
Research locations nearbySelect from list below to view details:
New York Medical CollegeValhalla, NY
Loading ...
Who is running the clinical trial?
Mitchell CairoLead Sponsor